Sodium glucose co-transport-2 (SGLT-2) inhibitors reduce tubular glucose reabsorption, producing a reduction of blood glucose without stimulating insulin release. Aim of this meta-analysis is the systematic collection of available data from randomized trials, in order to establish the durability of the efficacy of SGLT-2 inhibitors on glycemic control and body mass index.
Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials / Monami, Matteo; Liistro, Francesco; Scatena, Alessia; Nreu, Besmir; Mannucci, Edoardo. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - STAMPA. - (2018), pp. 0-0. [10.1111/dom.13221]
Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials
Monami, MatteoProject Administration
;Nreu, BesmirInvestigation
;Mannucci, EdoardoConceptualization
2018
Abstract
Sodium glucose co-transport-2 (SGLT-2) inhibitors reduce tubular glucose reabsorption, producing a reduction of blood glucose without stimulating insulin release. Aim of this meta-analysis is the systematic collection of available data from randomized trials, in order to establish the durability of the efficacy of SGLT-2 inhibitors on glycemic control and body mass index.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
